Gateway 2011: AMRI - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Gateway 2011: AMRI

Your online Gateway to AMRI in 2011

26 Corporate Circle
Albany, NY  12203
US: (518) 512-2000
Europe: +44 (0)1352 717100

About AMRI

AMRI is a global contract research and manufacturing organization with twenty years experience providing customers fully integrated lead discovery, development and manufacturing services. The company has steadily expanded, with more than 1400 employees located in facilities throughout the U.S., Europe and Asia


Its diverse customer portfolio includes companies in the pharmaceutical, specialty chemical, biotech, cosmetic, agriculture and food/beverage industries, as well as not-for-profit organizations, universities and medical institutions.
United in vision to provide the highest quality customer service experience, AMRI employees worldwide work together to provide scientific solutions that improve the quality of life.

New Whitepapers
AMRI Aseptic Fill and Finish Services
Formulations Capabilities at AMRI




blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here